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Abstract
Background: Lymphotoxin-alpha (LTA) is a pro-inflammatory cytokine with anti-tumor activity.
The objective of this study was to determine whether LTA polymorphisms influence the presence
of cancer.
Methods: LTA polymorphisms C804A (rs1041981, T60N) and T495C (rs2229094, C13R) were
determined in 1,536 consecutive autopsy cases and were registered in the Japanese single-
nucleotide polymorphisms (SNPs) for geriatric research (JG-SNP) Internet database. Tumors were
systematically reviewed, pathologically confirmed, and assessed in relation to LTA genotype.
Results: The study population consisted of 827 males and 709 females, with a mean age of 80
years. Altogether, we studied 606 subjects without cancer and 930 subjects with cancer of the
stomach (n = 183), lung (n = 164), colon or rectum (n = 143), or other sites. The presence of
cancer was higher in males than in females. The C804A and T495C polymorphisms were associated
with cancer in males (CA + AA: CC, adjusted OR = 0.72, 95% CI = 0.53 – 0.99; TC + CC: TT,
adjusted OR = 1.45, 95% CI = 1.04 – 2.02; respectively) but not in females. In males, the C804A
polymorphism was associated with lung cancer (CA + AA: CC, adjusted OR = 0.60, 95% CI = 0.37
– 0.97), whereas the T495C polymorphism was associated with gastric cancer (TC + CC: TT,
adjusted OR = 1.68, 95% CI = 1.06 – 2.65).
Conclusion: We found some evidence of an association between LTA polymorphisms and cancer
risk in elderly Japanese men. Further studies in larger populations should examine this hypothesis.
Background
Elderly people often experience chronic and low-grade
inflammation, whereupon the levels of certain inflamma-
tory serum markers (e.g., C-reactive protein) and pro-
inflammatory cytokines (e.g., tumor necrosis factor-alpha
and interleukin-6) are elevated. However, increases in cir-
culating inflammatory markers are often not noticeable in
healthy elderly persons and are much below the levels
experienced during acute infections [1,2]. Moreover, it is
well known that the prevalence of cancer increases sharply
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patients over the age of 65 [3]. Persistent inflammation is
thought to trigger certain cancers, particularly those of the
stomach, colon, and lung [4]. Although it has been estab-
lished that the risks of cancer and inflammation increase
with age [2], the influence of inflammatory cytokine pol-
ymorphisms on the genetic predisposition to cancer
remains unclear.
Lymphotoxin-alpha (LTA), a member of the tumor necro-
sis factor (TNF) family of cytokines, was initially isolated
on the basis of an anti-tumor activity. Later, this cytokine
was shown to have inflammatory and immunologic activ-
ities [5]. The LTA gene is located within the class III region
of the major histocompatibility complex (MHC) in chro-
mosome 6p21.3 [6]. LTA plays a key role in communica-
tion between lymphocytes and stromal cells, thereby
eliciting cytotoxic effects on cancer cells [7,8]. LTA induces
the expression of vascular cell-adhesion molecule 1
(VCAM1) on vascular endothelial cells and recruits natu-
ral killer (NK) cells to parenchymal organs and tumor
lesions [9]. NK cells have nonspecific host-defense mech-
anisms that aid in tumor rejection and protection from
metastases. Previous studies have shown that tumor
growth and metastasis are enhanced in LTA-deficient
mice, which produce NK cells that have reduced anti-
tumor potential [10,11]. Thus, LTA signaling plays an
important role in anti-tumor surveillance via the matura-
tion and recruitment of NK cells.
Previous studies have examined the relationship between
LTA polymorphisms and various cancers, and found that
the NcoI restriction fragment length polymorphism
(A252G) in the first intron is in tight linkage disequilib-
rium with C804A, resulting in the substitution of threo-
nine with asparagine at codon 60 in exon 3 [12,13]. The
LTA 252G allele increases LTA at the levels of mRNA and
protein [12]. Previous studies have found that the rela-
tionship between the risk of cancer and the rate of survival
among those with the LTA polymorphism varies accord-
ing to the cancer type [14-17]. However, the effect of LTA
polymorphisms on the presence of cancer in general is not
known.
Toward this end, we searched for two non-synonymous
polymorphisms, C804A (rs1041981, T60N) and T495C
(rs2229094, C13R), in consecutive autopsy cases and
determined whether they influenced cancer presence.
Methods
Subjects
The study population consisted of 1,536 consecutive
autopsy cases performed at the Tokyo Metropolitan Geri-
atric Hospital between 1995 and 2004. LTA polymor-
phisms were registered in the Internet database of
Japanese single-nucleotide polymorphisms (SNPs) for
geriatric research (JG-SNP) [18]. Subjects were enrolled
regardless of the cause of death and autopsies were per-
formed on 40% of patients who died at the hospital. The
study population included subjects who died from malig-
nant disease (33%), coronary heart disease (20%), and
pneumonia (13%). These proportions were similar to the
causes of death reported in a survey conducted by the
Ministry of Health, Labor and Welfare of Japan http://
www.mhlw.go.jp/toukei/saikin/hw/jinkou/tokusyu/
gaikoku07/09d.html which found that 30% of the Japa-
nese population died from malignant disease, 16% from
coronary heart disease, and 10% from pneumonia. The
presence, absence, and histopathology of cancers were
determined from autopsy findings. Histories of smoking
and alcohol drinking status were retrospectively deter-
mined from medical records, and subjects were classified
as smokers (including ex-smokers) versus non-smokers,
and alcohol drinkers versus non-drinkers. Information on
smoking and alcohol drinking status was missing from
109 and 118 patient histories, respectively. Written
informed consent was obtained from the family of each
patient at the time of autopsy. The study protocol was
approved by the ethical Committees of the Tokyo Metro-
politan Geriatric Hospital and the Tokyo Medical and
Dental University.
Genotyping
Genomic DNA was extracted from the renal cortex using a
standard procedure. LTA polymorphisms were genotyped
via melting curve analysis [19]. PCR primers and probes
were as follows. For LTA C804A (rs1041981, T60N): 5'-
GTT GGC CTC ACA CCT TCA-3' (forward primer), 5'-TGG
ATG CTT GGG TTC CTG-3' (reverse primer), CAG CAC
CCT CAA ACC TGC-Fluorescein (anchor probe), and LC
Red 640-GCT CAC CTC ATT GGT AAA CAT CCA CCT
GAC CTC C-Phosphate (detection probe). For LTA T495C
(rs2229094, C13R): 5'-CTC TTT CTC TGC AGG TTC TC-3'
(forward primer), 5'-GCT CTA GGG CTC AAG GTT T-3'
(reverse primer), CTC CCA AGG GTG GGT G-Fluorescein
(anchor probe), and LCRed640-CAC CAC CCT ACA CCT
CCT CCT TCT GG-Phosphate (detection probe). The PCR
amplification reaction was performed in 5 μl volume
using the LightCycler PCR kit (Roche Diagnostics, Penz-
berg, Germany). Each well contained 1 × PCR buffer, 4
mM of MgCl2, 0.2 mM of dNTPs, 0.05 μM of forward
primer, 0.5 μM of reverse primer, 0.2 μM of each anchor
and detection probe, 0.1 U of Faststart Taq polymerase,
and 10 ng of genomic DNA. The cycling protocol was per-
formed as follows: initial denaturation at 94°C for 10
min; followed by 40 cycles of 94°C for 15 sec, 55°C for
15 sec, and 72°C for 15 sec; and a final extension step at
72°C for 10 min. After completion of PCR, the plates were
heated from 40°C to 90°C with a gradient of 0.1°C per
second immediately before melting temperature analysisPage 2 of 6
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The genotype was determined based on melting profiles
automatically classified by LightCycler Genotyping soft-
ware (Roche Diagnostics). C804A and T495C polymor-
phisms were genotyped with success rates of 96% and
95%, respectively. Genotyping accuracy was confirmed by
sequencing randomly selected samples. The melting tem-
perature analysis correlated entirely with the direct
sequencing results.
Statistical analysis
Statistical analysis was performed using SAS software, ver-
sion 9.1.3 (SAS Institute Inc., Cary, NC). The distribution
of subjects with and without cancer, and associations with
other variables, were compared using Fisher's exact test.
Hardy-Weinberg equilibrium (HWE) was assessed using a
permutation test. Odds ratio (OR) and 95% confidence
interval (CI) were calculated using an unconditional
logistic regression model that compared genotype fre-
quencies in subjects with and without cancer, with respect
to LTA polymorphisms. The OR was adjusted by age, sex,
smoking, and alcohol drinking status. This study had a
statistical power of 0.8 to detect an OR of 1.5 in carriers of
at least one polymorphic allele, compared with carriers of
homozygous wild-type alleles. LTA haplotype frequencies
were estimated using Haploview software http://
www.broad.mit.edu/mpg/haploview/. Chi-square values
were calculated to determine the distribution of LTA hap-
lotypes among subjects with and without cancer. A prob-
ability level of 5% was considered statistically significant
for all analyses.
Results
Characteristics of the study subjects
Selected demographic variables, including the sites and
histological types of cancers, and risk factors are shown in
Table 1 (Additional file 1). The mean age of subjects was
80.2 ± 8.9 years. The study population consisted of 827
(54%) males and 709 (46%) females. Altogether, we stud-
ied 606 subjects without cancer and 930 subjects with
cancer. When the total number of subjects was divided by
the number of subjects over or under the median age of 80
years, the distributions of subjects with or without cancer
did not significantly differ. The frequency of cancer was
significantly higher in males than in females. No differ-
ences in smoking and alcohol drinking status between
cancer-bearing and cancer-free subjects were observed.
The most frequent sites of cancer were the stomach (n =
183), lung (n = 164), and colon or rectum (n = 143).
Genotype and allele frequencies of LTA polymorphisms
C804A and T495C were genotyped in all subjects. The
genotype frequencies of C804A were 37% for CC, 48% for
CA, and 15% for AA. The minor allele frequency was 39%,
and the allele distribution was consistent with HWE (p =
0.65). The genotype frequencies of T495C were 66% for
TT, 31% for TC, and 3% for CC. The minor allele fre-
quency was 19% and the allele distribution was consistent
with HWE (p = 0.48).
Association of LTA polymorphisms with cancer overall
The associations between C804A and T495C polymor-
phisms and the presence of cancer are shown in Table 2
(Additional file 1). Among cancer-free subjects, the fre-
quencies of the C804A genotypes CC, CA, and AA were
33%, 49%, and 18%, respectively, in males, and 33%,
54%, and 13%, respectively, in females (Table 3) (Addi-
tional file 1). In comparison with the CC genotype, the CA
genotype was associated with a significantly lower pres-
ence of cancer in all subjects (adjusted OR = 0.78, 95% CI
= 0.61 – 0.99). In males, the CA + AA genotype was asso-
ciated with a significantly lower presence of cancer com-
pared with the CC genotype (adjusted OR = 0.72, 95% CI
= 0.53 – 0.99). The association between the C804A poly-
morphism and cancer in females was not significant (CA
+ AA: CC, adjusted OR = 0.92, 95% CI = 0.66 – 1.29).
Additionally, cancer frequency was not associated with
C804A (data not shown).
In cancer-free subjects, the frequency of the T495C geno-
types TT, TC, and CC were 70%, 28%, and 2%, respec-
tively, in males, and 66%, 31%, and 3%, respectively, in
females (Table 3 in Additional file 1). Compared with the
TT genotype, the CC genotype was associated with a sig-
nificantly higher presence of cancer (adjusted OR = 2.24,
95% CI = 1.09 – 4.61). In males, the TC + CC genotype
was associated with a significantly higher presence of can-
cer, compared with the TT genotype (adjusted OR = 1.45,
95% CI = 1.04 – 2.02). The association between the
T495C polymorphism and cancer in females was not sig-
nificant (TC + CC: TT, adjusted OR = 1.08, 95% CI = 0.77
– 1.50).
Additionally, we explored the relationship between the
presence of C804A and T495C haplotypes and tumor for-
mation. C804A and T495C appeared to be present in
moderate linkage disequilibrium (r2 = 0.15, D' = 1.0) and
three major haplotypes were identified (495T-804C,
495T-804A, and 495C-804C). None of these haplotypes
were associated with the presence of cancer (data not
shown).
Association of LTA polymorphisms with specific types of 
cancers
Significant associations between LTA polymorphisms and
the presence of cancer in males prompted us to explore
the relationships between these polymorphisms and the
sites of cancer. After analyzing subjects with stomach,
lung, colorectal, prostate, breast, liver, biliary tract, kidney
or urinary tract, and hematopoietic malignancies, wePage 3 of 6
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phisms and lung and stomach cancers (Table 4 in Addi-
tional file 1). Among male subjects with lung cancer, the
C804A CA + AA genotype was associated with a signifi-
cantly lower presence of cancer than was the CC genotype
(adjusted OR = 0.60, 95% CI = 0.37–0.97). The associa-
tion between C804A polymorphism and lung cancer in
females was not significant (CA + AA: CC, adjusted OR =
0.65, 95% CI = 0.35 – 1.23).
The T495C polymorphism was not associated with the
presence of lung cancer, but the TC + CC genotype was
associated with a significantly higher presence of gastric
cancer in males, compared with the TT genotype (adjusted
OR = 1.68, 95% CI = 1.06–2.65). The association between
T495C polymorphism and gastric cancer was not signifi-
cant in females (TC + CC: TT, adjusted OR = 1.16, 95% CI
= 0.61 – 2.21).
Discussion
Our findings demonstrate that the LTA polymorphism
C804A is associated with a lower presence of cancer, par-
ticularly lung cancer, in elderly Japanese men, consistent
with previous studies showing that LTA has anti-tumor
activity.
Several laboratories have recently published a functional
analysis of the LTA C804A (T60N). Compared with the C
allele, the A allele is more bioactive with regards to the
induction of VCAM1 in cultured human coronary-artery
smooth muscle cells [13]. Furthermore, C804A is present
in very high linkage disequilibrium with another poly-
morphism, LTA A252G. These two polymorphisms have
been shown to be completely concordant in Japanese sub-
jects [16,17]. Compared with the A allele, the G allele of
the A252G genotype confers higher transcriptional activ-
ity in Jurkat cells [13] and phytohemagglutinin-stimu-
lated peripheral blood mononuclear cells [12]. Thus, the
C and A alleles are considered low and high bioactive alle-
les in LTA, respectively. Accordingly, the data suggest that
the lower presence of cancer in our study population may
reflect enhanced LTA activity because of the presence of
high-bioactive alleles.
The C804A and A252G polymorphisms have been stud-
ied with regards to cancer survival rates and risks of devel-
oping various type of cancer, including lung [14],
stomach [15,20,21], colorectal [22], breast [23], cervix
[16], endometrium [17] and bladder [24] cancers, as well
as leukemia [25], lymphoma [26,27], and myeloma [28].
The high-bioactive genotype was associated with the risk
of developing cancers of the lung [14], colon or rectum
[22], non-Hodgkin lymphoma [26,27], and myeloma
[28]. Low-bioactive genotypes were associated with the
risk of developing cervical [16] and endometrial cancers
[17], but not gastric [15,20,21], breast [23], bladder can-
cers [24], or leukemia [25]. These differences may be par-
tially explained by the multi-functionality of LTA. LTA can
promote cell growth and adhesion, and can potentially
favor the growth of certain tumors.
It remains unclear why C804A is associated with cancer in
males but not in females. However, gender is known to
play an important role in the development of various can-
cers. Recent studies also suggest that cytokine secretion
and innate immunity differ between the genders [29,30].
The C13R (T495C) polymorphism has not been as thor-
oughly studied as the T60N (C804A) polymorphism. Pre-
vious study reported there was not an association between
the T495C polymorphism and lung cancer [31]. The
T495C polymorphism is a haplotype component associ-
ated with altered LTA expression and increased levels of
vascular- and autoimmune-mediated inflammation [32].
These findings suggest that the T495C polymorphism is
also associated with cancer. We observed an association
between the C allele of the T495C polymorphism and the
presence of cancer, particularly gastric cancer. However, as
the minor allele frequency for this polymorphism was
low, these results must be confirmed in a larger study pop-
ulation.
The LTA gene is located within the class III region of the
MHC, in the 6p21.3 chromosome [6]. This region con-
tains many other genes, including that encoding the pro-
inflammatory cytokine, TNF. It is well-known that this
region shows high degrees of linkage disequilibrium.
Thus, associations identified in this study may reflect the
effects of other gene variants in this region.
As this was a hospital-based autopsy study, we had limited
access to information on lifestyle variables that could
potentially influence the development of cancer. Further-
more, although autopsies were performed on many of the
deaths (40%) that occurred in the hospital, and the causes
of death among our autopsy cases were similar to those
reported in a national survey, we cannot rule out the pos-
sibility of selection bias. Such bias can arise from chance
of admission, consent to autopsy, cause of death, and
autopsy practice. Survival bias is also a possibility, as par-
ticular genotypes may be associated with other diseases or
influence the lifespan of certain subjects, thereby intro-
ducing bias into the study population. However, the
C804A genotype frequency was similar to that reported in
other Japanese population studies [16,17], and any effects
of such possible bias did not cause our results to deviate
from HWE.Page 4 of 6
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We found some evidence of an association between LTA
polymorphisms and cancer risk in elderly Japanese men.
Further studies in larger populations should examine this
hypothesis.
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